![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
September 18, 2024
September 10, 2024
Tweets
;
The EA3211 clinical study is testing a potential new treatment for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: https://bit.ly/ea3211-study #hncsm
#ClinicalTrial EAQ222CD/CostCOM, led by @GelarehSadigh, is testing the effectiveness of cost communication and financial navigation in patients with #cancer. If you have any newly diagnosed #SolidCancer, you may be able to participate.
https://bit.ly/EAQ222CD
Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: http://bit.ly/indicate-trial #pcsm #ProstateCancerAware
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
46
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
